ION Acquisition Corp 2 Ltd. announced the pricing of its $220 million IPO this evening and its units are expected to begin trading on the NYSE under the symbol “IACB.U” Thursday, February 11.
The new company aims to focus on the rapidly growing universe of Israeli companies and entrepreneurs that apply technology and innovation to everyday lives. ION Acquisition Corp 2 is led by Chairman Jonathan Kolber, CEO Gilad Shany, CFO Anthony Reich, and President & COO Avrom Gilbert.
Total SPAC deal count for 2021 year-to-date is now 135 with $40.6 billion in gross proceeds raised. This offering is expected to close on Tuesday, February 16.
Goldman Sachs & Co. LLC and Morgan Stanley are serving as joint book-running managers for the offering. AmeriVet Securities is acting as co-manager for the offering. White & Case LLP is serving as Issuer’s Counsel with Greenberg Traurig, P.A. serving as Underwriter’s Counsel. Kost Forer Gabbay & Kasierer serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...
At the SPAC of Dawn Ever since Digital World announced its combination with Trump Media (NASDAQ:DJT) back in October 2021, it was clear that SPACworld and the Trump show were set to be intertwined for quite some time. And, although not every headline has a bearing on the wider SPAC world, Trump Media’s post-close rise...